Thyroid cancer (TC) is the most common endocrine neoplasia and is generally known to have a favorable prognosis. Nevertheless, differentiated thyroid cancer has the potential to be metastatic, and poorly differentiated thyroid cancer can present at an advanced clinical stage upon initial observation. This makes it difficult to assess the clinical characteristics and treatment outcomes after surgical intervention, and these patients subsequently have a low survival rate. Various diagnostic and treatment methodologies are currently being trialed to overcome these limitations, and efforts are being made to improve both the patient's prognosis and outcome.
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy and has a historically poor prognosis. Adjuvant therapy with mitotane, either alone or in combination with chemotherapy, is the standard of care treatment for ACC. Nevertheless, surgery remains the first line of curative treatment. Recently, several drugs targeting new pathways such as insulin growth factor 2 (IGF2), beta-catenin pathway, and others have entered clinical trials. Immunotherapy has also recently emerged as an important therapeutic option for several cancer models. However, the role of immunotherapy in the treatment cascade is as of yet not clear. Despite recent advances in the development of novel treatment methods ACC still has a dismal prognosis.
This Research Topic will invite the submission of research articles addressing how pathophysiology of endocrine malignancy development drives both the current and novel emerging therapies that can be of benefit to patients, in addition to the refinement and advancement of surgical interventions. It is intended to present and discuss all the aspects of the currently available diagnostic and treatment methodologies, be they surgical or otherwise, specifically of thyroid and adrenal malignancies via original research articles and reviews.
For this Research Topic we cordially invite authors and investigators to publish Original Research and Reviews highlighting the advancements in diagnosis, prognosis, surgery, and therapeutics of endocrine malignancies, especially Thyroid and Adrenocortical Cancer. Potential topics to be addressed may include, but are not limited to:
- Thyroid cancer diagnosis and differentiation
- Clinical management and surgical treatment of TC patients
- Adrenocortical cancer diagnosis; genetic, clinical and radiological findings
- New pathways, targeted drugs and immunotherapy for ACC patients
- Clinical management and surgical treatment of ACC patients
- Multiple Endocrine Neoplasia, genetic correlations and therapeutic approaches
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Thyroid cancer (TC) is the most common endocrine neoplasia and is generally known to have a favorable prognosis. Nevertheless, differentiated thyroid cancer has the potential to be metastatic, and poorly differentiated thyroid cancer can present at an advanced clinical stage upon initial observation. This makes it difficult to assess the clinical characteristics and treatment outcomes after surgical intervention, and these patients subsequently have a low survival rate. Various diagnostic and treatment methodologies are currently being trialed to overcome these limitations, and efforts are being made to improve both the patient's prognosis and outcome.
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy and has a historically poor prognosis. Adjuvant therapy with mitotane, either alone or in combination with chemotherapy, is the standard of care treatment for ACC. Nevertheless, surgery remains the first line of curative treatment. Recently, several drugs targeting new pathways such as insulin growth factor 2 (IGF2), beta-catenin pathway, and others have entered clinical trials. Immunotherapy has also recently emerged as an important therapeutic option for several cancer models. However, the role of immunotherapy in the treatment cascade is as of yet not clear. Despite recent advances in the development of novel treatment methods ACC still has a dismal prognosis.
This Research Topic will invite the submission of research articles addressing how pathophysiology of endocrine malignancy development drives both the current and novel emerging therapies that can be of benefit to patients, in addition to the refinement and advancement of surgical interventions. It is intended to present and discuss all the aspects of the currently available diagnostic and treatment methodologies, be they surgical or otherwise, specifically of thyroid and adrenal malignancies via original research articles and reviews.
For this Research Topic we cordially invite authors and investigators to publish Original Research and Reviews highlighting the advancements in diagnosis, prognosis, surgery, and therapeutics of endocrine malignancies, especially Thyroid and Adrenocortical Cancer. Potential topics to be addressed may include, but are not limited to:
- Thyroid cancer diagnosis and differentiation
- Clinical management and surgical treatment of TC patients
- Adrenocortical cancer diagnosis; genetic, clinical and radiological findings
- New pathways, targeted drugs and immunotherapy for ACC patients
- Clinical management and surgical treatment of ACC patients
- Multiple Endocrine Neoplasia, genetic correlations and therapeutic approaches
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
